KiOmed Pharma at ISIAT Congress 2025
KiOmed Pharma is pleased to participate in the 8th ISIAT Congress in Bucharest, where groundbreaking research on refractory knee osteoarthritis will be presented to the international medical community.
For the first time, an international panel of osteoarthritis experts has reached consensus on a standardized clinical definition of refractory knee osteoarthritis through a rigorous Delphi survey process. This achievement addresses a critical gap in clinical practice and research.
The Challenge: identifying patients
Knee osteoarthritis affects an estimated 7% of the global population, with nearly 70% experiencing knee involvement. While many patients find relief through standard treatments, a significant subset continues to suffer from persistent symptoms despite receiving guideline-based care.
Until now, the absence of a universally accepted definition for “refractory osteoarthritis” has complicated:
- Patient identification and stratification
- Clinical decision-making
- Trial design for emerging therapies
- Comparison of research outcomes across studies
Satellite Presentations at ISIAT 2025
Friday, October 3 | 14:00-14:20
“The Challenge of Refractory Osteoarthritis”
Professor Kirk Heusdens, Antwerp, Belgium
Professor Heusdens will present the findings from the Delphi consensus study, outlining the methodology and the robust criteria developed by the expert panel to define refractory osteoarthritis for clinical practice.
Key topics:
- The Delphi survey methodology and results
- Clinical criteria for identifying refractory OA patients
- Implications for patient management and future research
- Addressing the unmet needs of difficult-to-treat populations
Saturday, October 4 | 11:10-11:30
“Management of Patellofemoral Joint OA”
Professor Kirk Heusdens, Antwerp, Belgium
This session will showcase new clinical evidence on carboxymethyl-chitosan (CM-Chitosan) for managing patellofemoral joint osteoarthritis, including results from recent clinical trials.
Key topics:
- Clinical outcomes from the PIONEER randomized controlled trial
- Efficacy in traditionally non-responsive patient populations
- Safety profile and duration of effect
- Practical considerations for managing patellofemoral OA
The PIONEER study demonstrated that a single intra-articular injection of CM-Chitosan was safe and effective in an OA population with predictive factors of treatment failure, showing sustained improvements in symptoms and physical function for 12 months.
Visit out team at ISIAT 2025
📍Venue: Pullman Bucharest World Trade Center – Booth 1
📅Dates: October 2-4, 2025
